Drug Profile
Research programme: recombinant human protein therapeutics - Sinobiomed
Latest Information Update: 26 Jan 2011
Price :
$50
*
At a glance
- Originator Sinobiomed
- Class Recombinant proteins
- Mechanism of Action Hepatocyte growth factor stimulants; Kallikrein 1 stimulants; Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Liver disorders; Pancreatitis; Peripheral vascular disorders; Stroke; Thrombosis
Most Recent Events
- 21 Aug 2008 Preclinical trials in Liver disorders in China (Parenteral)
- 21 Aug 2008 Preclinical trials in Pancreatitis in China (Parenteral)
- 21 Aug 2008 Preclinical trials in Peripheral vascular disorders in China (Parenteral)